In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.25, denoting a +2% change from the preceding trading day.
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Gilead Sciences (GILD) reachead $112.39 at the closing of the latest trading day, reflecting a +0.45% change compared to its last close.
In the most recent trading session, Gilead Sciences (GILD) closed at $111.88, indicating a +0.54% shift from the previous trading day.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in sentiment toward an entire sector.
When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in sentiment toward an entire sector.
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?
Here is how Gilead Sciences (GILD) and AngioDynamics (ANGO) have performed compared to their sector so far this year.